Engineered Lysin Therapy Enters Real-World Clinical Use Against Chronic Drug-Resistant Joint Infection
Experimental antibacterial protein ClyO begins extended treatment under FDA expanded access program
For decades, antibiotics have been the cornerstone of treating bacterial infections. However, the global rise of antimicrobial resistance and the ability of bacteria to form protective biofilms on implanted medical devices have created an urgent need for entirely new antibacterial strategies.
One such approach is now being tested in one of the most challenging clinical settings.
US biotechnology company Precisio Biotix Therapeutics has announced that its investigational engineered lysin ClyO (LYSG101) is being administered under an FDA Expanded Access protocol to a patient suffering from a seven-year chronic multidrug-resistant prosthetic joint infection (PJI).
Treatment began on June 1, 2026, as part of a planned four-month dosing regimen, followed by at least six months of clinical observation. While the case involves only a single patient, it represents one of the first prolonged real-world evaluations of an engineered lysin in a chronic implant-associated infection.
Why Prosthetic Joint Infections Are So Difficult to Treat
Joint replacement surgeries have transformed the lives of millions of patients worldwide. However, infections involving artificial hips or knees remain among the most devastating complications.
Unlike many acute bacterial infections, bacteria attached to prosthetic implants can organize into biofilms—complex communities embedded within a protective matrix.
Inside these biofilms, bacteria become far more difficult to eliminate.
Biofilms shield bacteria from immune cells, reduce antibiotic penetration, and allow dormant bacterial populations to survive even prolonged antibiotic treatment. As a result, many patients require repeated surgeries, long-term suppressive antibiotics, or complete replacement of the implanted joint.
The patient receiving ClyO had reportedly undergone multiple surgical procedures and years of antibiotic suppression without achieving lasting infection control.
What Is ClyO?
ClyO belongs to a new class of antibacterial biologics known as lysins.
Unlike conventional antibiotics that interfere with bacterial metabolism or protein synthesis, lysins are enzymes that directly attack the bacterial cell wall.
They specifically cleave peptidoglycan, the structural scaffold that maintains bacterial integrity. Once the cell wall is disrupted, the bacterium rapidly bursts and dies.
Because lysins attack an essential structural component of bacteria rather than many traditional drug targets, they may remain effective against organisms resistant to multiple antibiotic classes.
ClyO has been engineered specifically to target Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA), as well as coagulase-negative staphylococci—two of the most common causes of prosthetic joint infections.
Encouraging Early Signs—but Far from Proof
According to Precisio Biotix, more than one month after treatment initiation, the therapy has been well tolerated with no reported adverse events.
Cultures obtained from the infected knee have also remained negative.
Although these findings are encouraging, researchers emphasize that they should not be interpreted as evidence that the infection has been cured.
Negative cultures during active treatment do not necessarily indicate complete eradication of bacteria.
Biofilm-associated organisms can remain hidden within tissues or on implant surfaces and may recur months after therapy ends.
Furthermore, because the treatment involves only a single expanded-access patient without a control group, it is impossible to determine whether ClyO alone produced the observed response.
The real test will come after treatment is completed and long-term follow-up begins.
A New Weapon Against Biofilms?
One reason ClyO has attracted attention is its preclinical activity against bacterial biofilms.
Laboratory studies demonstrated that the molecule rapidly killed both methicillin-sensitive and methicillin-resistant Staphylococcus aureus, disrupted mature biofilms, and remained active in multiple animal infection models.
Perhaps most notably, researchers reported no detectable resistance after 100 consecutive laboratory passages, suggesting that bacteria may find it more difficult to evolve resistance against this mechanism compared with conventional antibiotics.
However, scientists caution that laboratory experiments cannot fully predict how bacteria will behave during prolonged treatment in human patients.
Long-term clinical studies will be required to determine whether resistance eventually emerges.
Learning from Previous Setbacks
The lysin field has experienced both excitement and disappointment.
One of the best-known lysin programs, exebacase, generated promising early clinical data against Staphylococcus aureus bloodstream infections but ultimately failed to demonstrate benefit in a Phase III clinical trial.
That experience highlighted an important lesson: strong laboratory activity does not always translate into clinical success.
Researchers believe ClyO may face different biological challenges because prosthetic joint infections differ substantially from bloodstream infections, particularly due to the presence of mature biofilms.
Whether this translates into improved clinical outcomes remains unknown.
More Than Antibiotics—or an Addition to Them?
If future studies confirm its effectiveness, ClyO is unlikely to replace surgery or antibiotics entirely.
Instead, clinicians envision lysins as adjunctive therapies that could:
- Reduce bacterial burden before surgery
- Improve implant retention
- Enhance the activity of conventional antibiotics
- Reduce dependence on prolonged suppressive antibiotic therapy
- Offer new options for patients who have exhausted standard treatments
Such an approach could be particularly valuable as antimicrobial resistance continues to rise worldwide.
The Road Ahead
Expanded-access cases are designed primarily to provide treatment options for patients with serious conditions while generating preliminary clinical insights.
They cannot establish efficacy.
The next critical milestone for ClyO will be carefully designed clinical trials evaluating:
- Long-term infection-free survival
- Prevention of recurrence
- Safety following repeated dosing
- Immune responses against the protein
- Pharmacokinetics within bone and biofilm tissue
- Reduced need for revision surgery
For now, ClyO represents an intriguing example of how engineered biological molecules may complement—or someday reshape—the treatment of chronic bacterial infections.
Whether lysins become a new class of anti-infective medicines will ultimately depend not on a single promising case, but on reproducible evidence across well-controlled clinical trials.
Why This Matters
- First prolonged clinical use of engineered lysin ClyO (LYSG101) under FDA Expanded Access.
- Targets biofilm-associated prosthetic joint infections, among the hardest bacterial infections to treat.
- Represents a new antibacterial mechanism distinct from conventional antibiotics.
- Could open a new therapeutic avenue against multidrug-resistant Staphylococcus infections if larger clinical studies are successful.
Listen to Podcast
https://sites.libsyn.com/482703/lysins-a-next-generation-treatment-option-for-pji-part-1
https://sites.libsyn.com/482703/lysins-a-next-generation-treatment-option-for-pji-part-2
